These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37792386)
21. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. Song YC; Liu SJ; Lee HJ; Liao HC; Liu CT; Wu MY; Yen HR J Microbiol Immunol Infect; 2023 Aug; 56(4):705-717. PubMed ID: 37055256 [TBL] [Abstract][Full Text] [Related]
22. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G Front Immunol; 2021; 12():737083. PubMed ID: 34539673 [TBL] [Abstract][Full Text] [Related]
23. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813 [TBL] [Abstract][Full Text] [Related]
24. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection. Sedegah M; Porter C; Goguet E; Ganeshan H; Belmonte M; Huang J; Belmonte A; Inoue S; Acheampong N; Malloy AMW; Hollis-Perry M; Jackson-Thompson B; Ramsey KF; Alcorta Y; Maiolatesi SE; Wang G; Reyes AE; Illinik L; Sanchez-Edwards M; Burgess TH; Broder CC; Laing ED; Pollett SD; Villasante E; Mitre E; Hollingdale MR PLoS One; 2022; 17(10):e0276241. PubMed ID: 36251675 [TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults. Jin Z; Wu J; Wang Y; Huang T; Zhao K; Liu J; Wang H; Zhu T; Gou J; Huang H; Wu X; Yin H; Song J; Li R; Zhang J; Li L; Chen J; Li X; Zhang M; Li J; Hou M; Song Y; Wang B; Gao Q; Wu L; Kong Y; Dong R J Infect; 2023 Dec; 87(6):556-570. PubMed ID: 37898410 [TBL] [Abstract][Full Text] [Related]
26. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants. Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765 [TBL] [Abstract][Full Text] [Related]
27. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D Front Immunol; 2022; 13():1017863. PubMed ID: 36248803 [TBL] [Abstract][Full Text] [Related]
28. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961 [TBL] [Abstract][Full Text] [Related]
29. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. Sokal A; Bastard P; Chappert P; Barba-Spaeth G; Fourati S; Vanderberghe A; Lagouge-Roussey P; Meyts I; Gervais A; Bouvier-Alias M; Azzaoui I; Fernández I; de la Selle A; Zhang Q; Bizien L; Pellier I; Linglart A; Rothenbuhler A; Marcoux E; Anxionnat R; Cheikh N; Léger J; Amador-Borrero B; Fouyssac F; Menut V; Goffard JC; Storey C; Demily C; Mallebranche C; Troya J; Pujol A; Zins M; Tiberghien P; Gray PE; McNaughton P; Sullivan A; Peake J; Levy R; Languille L; Rodiguez-Gallego C; Boisson B; Gallien S; Neven B; Michel M; Godeau B; Abel L; Rey FA; Weill JC; Reynaud CA; Tangye SG; Casanova JL; Mahévas M J Exp Med; 2023 Jan; 220(1):. PubMed ID: 36342455 [TBL] [Abstract][Full Text] [Related]
30. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination. Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876 [TBL] [Abstract][Full Text] [Related]
31. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study. Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030 [TBL] [Abstract][Full Text] [Related]
32. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines. Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals. Hayer J; Urlaub E Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594 [TBL] [Abstract][Full Text] [Related]
35. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. Mangia A; Serra N; Cocomazzi G; Giambra V; Antinucci S; Maiorana A; Giuliani F; Montomoli E; Cantaloni P; Manenti A; Piazzolla V Front Public Health; 2022; 10():847384. PubMed ID: 35433614 [TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response. Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096 [TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632 [TBL] [Abstract][Full Text] [Related]
39. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination]. Yürüker Ö; Yetkin O; Güvenir M Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217 [TBL] [Abstract][Full Text] [Related]